Open Access
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
Тип публикации: Journal Article
Дата публикации: 2021-02-26
scimago Q1
wos Q1
БС1
SJR: 10.416
CiteScore: 48.4
Impact factor: 45.8
ISSN: 00368075, 10959203
PubMed ID:
33495306
Multidisciplinary
Краткое описание
Hurting the virus by targeting the host
Many host proteins play a role in the life cycle of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and some are required for viral replication and translation. There are efforts toward finding drugs that target viral proteins, but a complementary approach is to target these required host proteins. White et al. explored the antiviral activity of the cyclic depsipeptide drug plitidepsin, which targets the hosts cell's translational machinery (see the Perspective by Wong and Damania). The authors show that in cells, the drug is substantially more potent than remdesivir against SARS-CoV-2, with limited cellular toxicity. Prophylactic treatment protected mice against SARS-CoV-2 infection, so further investigation of plitidepsin as a therapeutic is warranted.
Science
, this issue p.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Топ-30
Журналы
|
2
4
6
8
10
12
|
|
|
Marine Drugs
11 публикаций, 3.74%
|
|
|
bioRxiv
8 публикаций, 2.72%
|
|
|
International Journal of Molecular Sciences
7 публикаций, 2.38%
|
|
|
Molecules
7 публикаций, 2.38%
|
|
|
Journal of Natural Products
7 публикаций, 2.38%
|
|
|
Frontiers in Immunology
6 публикаций, 2.04%
|
|
|
Viruses
5 публикаций, 1.7%
|
|
|
Nature Communications
5 публикаций, 1.7%
|
|
|
Cell
5 публикаций, 1.7%
|
|
|
mBio
4 публикации, 1.36%
|
|
|
Nature
4 публикации, 1.36%
|
|
|
Antiviral Research
4 публикации, 1.36%
|
|
|
International Journal of Biological Macromolecules
4 публикации, 1.36%
|
|
|
Pharmaceuticals
3 публикации, 1.02%
|
|
|
Frontiers in Pharmacology
3 публикации, 1.02%
|
|
|
Antimicrobial Agents and Chemotherapy
3 публикации, 1.02%
|
|
|
Briefings in Bioinformatics
3 публикации, 1.02%
|
|
|
Science
2 публикации, 0.68%
|
|
|
Scientific Reports
2 публикации, 0.68%
|
|
|
Nature Microbiology
2 публикации, 0.68%
|
|
|
Microorganisms
2 публикации, 0.68%
|
|
|
Pharmaceutics
2 публикации, 0.68%
|
|
|
Frontiers in Molecular Biosciences
2 публикации, 0.68%
|
|
|
Frontiers in Marine Science
2 публикации, 0.68%
|
|
|
Amino Acids
2 публикации, 0.68%
|
|
|
npj Digital Medicine
2 публикации, 0.68%
|
|
|
Communications Biology
2 публикации, 0.68%
|
|
|
Bioorganic Chemistry
2 публикации, 0.68%
|
|
|
Acta Pharmaceutica Sinica B
2 публикации, 0.68%
|
|
|
2
4
6
8
10
12
|
Издатели
|
10
20
30
40
50
60
|
|
|
Elsevier
60 публикаций, 20.41%
|
|
|
MDPI
44 публикации, 14.97%
|
|
|
Springer Nature
41 публикация, 13.95%
|
|
|
Cold Spring Harbor Laboratory
31 публикация, 10.54%
|
|
|
Frontiers Media S.A.
18 публикаций, 6.12%
|
|
|
American Chemical Society (ACS)
17 публикаций, 5.78%
|
|
|
Wiley
17 публикаций, 5.78%
|
|
|
American Society for Microbiology
13 публикаций, 4.42%
|
|
|
Oxford University Press
9 публикаций, 3.06%
|
|
|
Taylor & Francis
6 публикаций, 2.04%
|
|
|
Royal Society of Chemistry (RSC)
4 публикации, 1.36%
|
|
|
Bentham Science Publishers Ltd.
4 публикации, 1.36%
|
|
|
American Association for the Advancement of Science (AAAS)
2 публикации, 0.68%
|
|
|
Rockefeller University Press
2 публикации, 0.68%
|
|
|
IGI Global
2 публикации, 0.68%
|
|
|
Canadian Science Publishing
1 публикация, 0.34%
|
|
|
Microbiology Society
1 публикация, 0.34%
|
|
|
Spandidos Publications
1 публикация, 0.34%
|
|
|
Baishideng Publishing Group
1 публикация, 0.34%
|
|
|
SAGE
1 публикация, 0.34%
|
|
|
Huazhong University of Science and Technology
1 публикация, 0.34%
|
|
|
Pensoft Publishers
1 публикация, 0.34%
|
|
|
Korean Society for Microbiology and Biotechnology
1 публикация, 0.34%
|
|
|
The Japan Institute of Heterocyclic Chemistry
1 публикация, 0.34%
|
|
|
Hindawi Limited
1 публикация, 0.34%
|
|
|
American Association for Cancer Research (AACR)
1 публикация, 0.34%
|
|
|
eLife Sciences Publications
1 публикация, 0.34%
|
|
|
Japanese Society of Fisheries Science
1 публикация, 0.34%
|
|
|
Mark Allen Group
1 публикация, 0.34%
|
|
|
10
20
30
40
50
60
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
294
Всего цитирований:
294
Цитирований c 2025:
38
(12.92%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
White K. M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A // Science. 2021. Vol. 371. No. 6532. pp. 926-931.
ГОСТ со всеми авторами (до 50)
Скопировать
White K. M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A // Science. 2021. Vol. 371. No. 6532. pp. 926-931.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1126/science.abf4058
UR - https://doi.org/10.1126/science.abf4058
TI - Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
T2 - Science
AU - White, Kris M
AU - Rosales, Romel
AU - Yildiz, Soner
AU - Kehrer, Thomas
AU - Miorin, Lisa
AU - Moreno, E.
AU - Jangra, Sonia
AU - Uccellini, Melissa B
AU - Rathnasinghe, Raveen
AU - Coughlan, Lynda
AU - Martínez-Romero, Carles
AU - Batra, Jyoti
AU - Rojc, Ajda
AU - Bouhaddou, Mehdi
AU - Fabius, Jacqueline M
AU - Obernier, Kirsten
AU - Dejosez, Marion
AU - Guillén, María José
AU - Losada, Alejandro
AU - Avilés, Pablo
AU - Schotsaert, M.
AU - Zwaka, Thomas P.
AU - Vignuzzi, Marco
AU - Shokat, Kevan M.
AU - Krogan, Nevan J.
AU - García-Sastre, Adolfo
PY - 2021
DA - 2021/02/26
PB - American Association for the Advancement of Science (AAAS)
SP - 926-931
IS - 6532
VL - 371
PMID - 33495306
SN - 0036-8075
SN - 1095-9203
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2021_White,
author = {Kris M White and Romel Rosales and Soner Yildiz and Thomas Kehrer and Lisa Miorin and E. Moreno and Sonia Jangra and Melissa B Uccellini and Raveen Rathnasinghe and Lynda Coughlan and Carles Martínez-Romero and Jyoti Batra and Ajda Rojc and Mehdi Bouhaddou and Jacqueline M Fabius and Kirsten Obernier and Marion Dejosez and María José Guillén and Alejandro Losada and Pablo Avilés and M. Schotsaert and Thomas P. Zwaka and Marco Vignuzzi and Kevan M. Shokat and Nevan J. Krogan and Adolfo García-Sastre and others},
title = {Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A},
journal = {Science},
year = {2021},
volume = {371},
publisher = {American Association for the Advancement of Science (AAAS)},
month = {feb},
url = {https://doi.org/10.1126/science.abf4058},
number = {6532},
pages = {926--931},
doi = {10.1126/science.abf4058}
}
Цитировать
MLA
Скопировать
White, Kris M., et al. “Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.” Science, vol. 371, no. 6532, Feb. 2021, pp. 926-931. https://doi.org/10.1126/science.abf4058.